Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Oct 11, 2010 9:05am
455 Views
Post# 17551077

RE: Slow & Steady John Ing & The Silly Season??

RE: Slow & Steady John Ing & The Silly Season??Oil:

[S] Here is another Goldbug who has had my attention for the past 25 years. Like John Embry, John Ing is one of the few "analysts"/Goldbugs who have been putting their clients money where their mouths are most recently at Sprott for JE and Maison Placements for JI).

Here is what he had to say on BNN back on May 11th of this year.

https://www.gold-prices.biz/john-ing-comments-on-the-record-gold-price/


https://www.gold-prices.biz/john-embry-discusses-gold-and-silver-on-bnn/


https://watch.bnn.ca/commodities/october-2010/commodities-october-6-2010/#clip357302


BWDIK? While some of us here might have a BRD (PROPERTY) bias, we believe that BRD may have a lot more going for it compared to SAS. John Ing does give kudos to JPerron for his excellent job on SAS. Just imagine what Perron could have done with APG. BRD continues to improve the balance sheet especially with the U/G contribution coming on stream to displace some of the LG (and problematic) Open Pit Watch out for the silly season. Haywood's signal calling have taken BRD to new (recent) weekly highs.

GLTAL - GLAP

Cheers
Stanley
Bullboard Posts